Literature DB >> 22692814

Risk factors for fractures and avascular osteonecrosis in type 1 Gaucher disease: a study from the International Collaborative Gaucher Group (ICGG) Gaucher Registry.

Aneal Khan1, Thomas Hangartner, Neal J Weinreb, John S Taylor, Pramod K Mistry.   

Abstract

We hypothesized that overall disease activity or the severity of involvement of individual disease compartments, as measured by clinical and surrogate markers, predict the risk of avascular osteonecrosis (AVN) or fractures in type 1 Gaucher disease (GD1). We applied our risk-set matched case-control method to identify four patient groups within the International Collaborative Gaucher Group (ICGG) Gaucher Registry based on the presence and absence of AVN and fractures. Characteristics of GD1 were examined by comparing the distributions of each risk factor in cases versus matched controls using conditional logistic regression to calculate adjusted odds ratios (OR). Potential risk factors included hematological and visceral parameters, GD1 biomarkers, white blood cells, GBA1 genotype, and spine and femur dual-energy X-ray absorptiometry (DXA) Z-scores. In the total population of 5894 ICGG Gaucher Registry patients, 544 experienced at least one episode of AVN; 2008 reported no history of AVN. Clinical and surrogate markers of disease activity were similar in patients with and without AVN; patients with AVN were 1.6 times more likely to be anemic compared to matched controls (OR = 1.59; 95% confidence interval [CI], 1.06-2.38, p < 0.05). For fractures, 319 patients suffered fractures and 1233 had no prior history of fractures. Clinical and surrogate markers of disease in patients with and without fractures were similar, except for mean lumbar spine DXA Z-scores. Among patients with fractures, 49.3% had DXA Z-scores ≤ -1 compared to 31.0% in the control group. Compared to controls with Z-scores > -1.0, GD1 patients exhibiting Z-scores ≤ -1 had an OR of 5.55 (95% CI, 1.81-17.02, p < 0.01) for fracture. In GD1, after controlling for gender, year of birth, treatment status, and splenectomy status, we identified new risk factors for AVN and fractures. Concurrent anemia was associated with an increased risk for AVN. Low bone mineral density of the lumbar spine was a strong risk factor for fractures of the spine and femur in GD1.
Copyright © 2012 American Society for Bone and Mineral Research.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22692814     DOI: 10.1002/jbmr.1680

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  24 in total

1.  Aberrant progranulin, YKL-40, cathepsin D and cathepsin S in Gaucher disease.

Authors:  Yuliya Afinogenova; Jiapeng Ruan; Ruhua Yang; Nathaniel Kleytman; Gregory Pastores; Andrew Lischuk; Pramod K Mistry
Journal:  Mol Genet Metab       Date:  2019-07-23       Impact factor: 4.797

Review 2.  Gaucher disease.

Authors:  Aabha Nagral
Journal:  J Clin Exp Hepatol       Date:  2014-04-21

Review 3.  Gaucher disease: the metabolic defect, pathophysiology, phenotypes and natural history.

Authors:  Hagit N Baris; Ian J Cohen; Pramod K Mistry
Journal:  Pediatr Endocrinol Rev       Date:  2014-09

4.  Unexpected macrophage-independent dyserythropoiesis in Gaucher disease.

Authors:  Nelly Reihani; Jean-Benoit Arlet; Michael Dussiot; Thierry Billette de Villemeur; Nadia Belmatoug; Christian Rose; Yves Colin-Aronovicz; Olivier Hermine; Caroline Le Van Kim; Melanie Franco
Journal:  Haematologica       Date:  2016-07-28       Impact factor: 9.941

Review 5.  Evaluation of an imaging biomarker, Dixon quantitative chemical shift imaging, in Gaucher disease: lessons learned.

Authors:  L van Dussen; E M Akkerman; C E M Hollak; A J Nederveen; M Maas
Journal:  J Inherit Metab Dis       Date:  2014-06-13       Impact factor: 4.982

6.  Improvement in Bone Mineral Density and Architecture in a Patient with Gaucher Disease Using Teriparatide.

Authors:  Aneal Khan; David A Hanley; Colleen McNeil; Steven Boyd
Journal:  JIMD Rep       Date:  2015-03-03

Review 7.  Gaucher disease: the role of the specialist on metabolic bone diseases.

Authors:  Laura Masi; Maria Luisa Brandi
Journal:  Clin Cases Miner Bone Metab       Date:  2015-10-26

Review 8.  Enzyme replacement and substrate reduction therapy for Gaucher disease.

Authors:  Elad Shemesh; Laura Deroma; Bruno Bembi; Patrick Deegan; Carla Hollak; Neal J Weinreb; Timothy M Cox
Journal:  Cochrane Database Syst Rev       Date:  2015-03-27

Review 9.  Gaucher disease: Basic and translational science needs for more complete therapy and management.

Authors:  Gregory A Grabowski; Armand H M Antommaria; Edwin H Kolodny; Pramod K Mistry
Journal:  Mol Genet Metab       Date:  2020-12-29       Impact factor: 4.797

Review 10.  Gaucher disease - more than just a rare lipid storage disease.

Authors:  Jaehyeok Roh; Subbaya Subramanian; Neal J Weinreb; Reena V Kartha
Journal:  J Mol Med (Berl)       Date:  2022-01-23       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.